Aeterna Zentaris Inc. (AEZS) Earns Buy Rating from HC Wainwright
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Sunday. They currently have a $12.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 242.86% from the stock’s current price.
Several other research firms have also commented on AEZS. Canaccord Genuity restated a “buy” rating and set a $9.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, August 23rd. Zacks Investment Research upgraded Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Monday, August 15th. Finally, Maxim Group restated a “buy” rating and set a $11.00 price target on shares of Aeterna Zentaris in a research report on Saturday, August 13th.
Aeterna Zentaris (NASDAQ:AEZS) opened at 3.50 on Friday. The company’s 50-day moving average price is $3.79 and its 200 day moving average price is $3.56. The stock’s market capitalization is $34.79 million. Aeterna Zentaris has a 52 week low of $2.60 and a 52 week high of $15.70.
About Aeterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Stock Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related stocks with our FREE daily email newsletter.